Pembrolizumab/placebo más paclitaxel con o sin bevacizumab para el cáncer de ovario recurrente resistente al platino
The primary objective is to compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab, with respect to progression-free survival (PFS) per Response Evaluation Criteria